Cargando…
Lower mortality following pulmonary adverse events and sepsis with ticagrelor compared to clopidogrel in the PLATO study
In the PLATelet inhibition and patient Outcomes (PLATO) study of patients with acute coronary syndromes, ticagrelor reduced mortality compared to clopidogrel but the mechanisms for this mortality reduction remain uncertain. We analysed adverse events (AEs) consistent with either pulmonary infection...
Autores principales: | Storey, Robert F., James, Stefan K., Siegbahn, Agneta, Varenhorst, Christoph, Held, Claes, Ycas, Joseph, Husted, Steen E., Cannon, Christopher P., Becker, Richard C., Steg, Ph Gabriel, Åsenblad, Nils, Wallentin, Lars |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Informa UK Ltd.
2014
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4220996/ https://www.ncbi.nlm.nih.gov/pubmed/24127651 http://dx.doi.org/10.3109/09537104.2013.842965 |
Ejemplares similares
-
Ticagrelor vs. clopidogrel in patients with non-ST-elevation acute coronary syndrome with or without revascularization: results from the PLATO trial
por: Lindholm, Daniel, et al.
Publicado: (2014) -
Ticagrelor Versus Clopidogrel in Patients With Acute Coronary Syndromes and Chronic Obstructive Pulmonary Disease: An Analysis From the Platelet Inhibition and Patient Outcomes (PLATO) Trial
por: Andell, Pontus, et al.
Publicado: (2015) -
Ticagrelor versus clopidogrel in patients with acute coronary syndromes intended for non-invasive management: substudy from prospective randomised PLATelet inhibition and patient Outcomes (PLATO) trial
por: James, Stefan K, et al.
Publicado: (2011) -
Time-based measures of treatment effect: reassessment of ticagrelor and clopidogrel from the PLATO trial
por: Bellavia, Andrea, et al.
Publicado: (2017) -
Ticagrelor vs. clopidogrel in patients with acute coronary syndromes and diabetes: a substudy from the PLATelet inhibition and patient Outcomes (PLATO) trial
por: James, Stefan, et al.
Publicado: (2010)